Synthesis of 225Ac-PSMA-617 for Preclinical Use | Bentham Science
PSMAtreatment - What is actinium PSMA - PSMA Forum
Efficacy and safety of Ac-225-PSMA-617 TAT in Prostate Cancer - Oncidium Foundation
![Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00722/article_deploy/html/images/pharmaceutics-13-00722-g002.png "Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis")
Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA - European Urology
![18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-17460-0/MediaObjects/41598_2022_17460_Fig1_HTML.png "18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports")
18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports
Lu-177 PSMA therapy vs Ac-225 PSMA therapy
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 | EJNMMI Research | Full Text
![Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00715/article_deploy/html/images/pharmaceutics-13-00715-g001.png "Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC")
Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy - ScienceDirect
Prof.Dr.LEVENT KABASAKAL | Ac-225-PSMA for Castration Resistant Metastatic Prostate Cancer
A) 68 Ga-PSMA-11 PET/CT scan of patient with pretherapeutic tumor... | Download Scientific Diagram
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient - Omer Aras, Stefan Harmsen, Richard Ting, Haluk B Sayman, 2021
ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist
Novel radioligand therapy proven superior for | EurekAlert!
Brazilian Journal Of Oncology - Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report
Ac-225 PSMA therapy
225Ac-PSMA-617 for Therapy of Prostate Cancer - ScienceDirect
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
![Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/23/jnumed.123.265546/F6.large.jpg "Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine")
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram
Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. | Semantic Scholar
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
![Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617](https://pub.mdpi-res.com/cancers/cancers-14-05651/article_deploy/html/images/cancers-14-05651-ag.png?1669355153 "Cancers | Free Full-Text | [225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA -617")